This Week: DMT Study Skips Set and Setting Cybin Acquires Entheon’s Phase 1 DMT Study FDA Snubs Mydecine’s Seamless Trial Design Eleusis Scraps SPAC and more… DMT Study Skips Set and Setting This week we take a closer look at a recent publication out of Yale and VA Connecticut Healthcare System. This exploratory study sought to ascertain the safety, tolerability and efficacy of DMT in a small…


Previous articleKambô: Another Psychedelic Amphibian?
Next articlePT327 – Rick Doblin, Ph.D. – Confronting Abuse in Clinical Trials and the Future of Psychedelic Medicine